KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non Operating Income (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 15 years of Other Non Operating Income data on record, last reported at $102000.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 114.55% year-over-year to $102000.0; the TTM value through Sep 2025 reached -$8.7 million, down 216.43%, while the annual FY2025 figure was -$2.6 million, 68.61% up from the prior year.
  • Other Non Operating Income reached $102000.0 in Q3 2025 per JAZZ's latest filing, up from -$1.8 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $9.4 million in Q4 2023 and bottomed at -$10.5 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is -$1.4 million, with a median of -$1.5 million recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: surged 735.78% in 2021, then plummeted 1217.71% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$5.6 million in 2021, then surged by 55.77% to -$2.5 million in 2022, then surged by 476.83% to $9.4 million in 2023, then tumbled by 167.3% to -$6.3 million in 2024, then surged by 101.62% to $102000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $102000.0 in Q3 2025, -$1.8 million in Q2 2025, and -$6.3 million in Q4 2024.